Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | $140.00 → $132.00 | Outperform → Neutral | Mizuho |
| 1/31/2025 | $119.00 → $132.00 | Buy → Hold | Canaccord Genuity |
| 9/6/2024 | $68.00 → $92.00 | Neutral → Overweight | Piper Sandler |
| 1/3/2024 | $83.00 | Outperform | Robert W. Baird |
| 12/11/2023 | $75.00 | Outperform | TD Cowen |
| 4/20/2023 | $80.00 | Overweight | Morgan Stanley |
| 8/22/2022 | $64.00 → $49.00 | Buy → Neutral | Goldman |
| 7/7/2022 | $74.00 | Buy | Mizuho |
Mizuho downgraded Intra-Cellular Therapies from Outperform to Neutral and set a new price target of $132.00 from $140.00 previously
Canaccord Genuity downgraded Intra-Cellular Therapies from Buy to Hold and set a new price target of $132.00 from $119.00 previously
Piper Sandler upgraded Intra-Cellular Therapies from Neutral to Overweight and set a new price target of $92.00 from $68.00 previously